Intravenous Immune Globulin for the Treatment of Autoimmune Mucocutaneous Blistering Diseases

IVIg is covered for biopsy-proven Pemphigus Vulgaris, Pemphigus Foliaceus, Bullous Pemphigoid, Mucous Membrane (Cicatricial) Pemphigoid, and Epidermolysis Bullosa Acquisita in patients who have failed conventional therapy, in whom conventional therapy is contraindicated, or with rapidly progressive disease requiring short-term bridge therapy. Coverage requires biopsy confirmation and documentation of failure/contraindication/rapid progression and is limited to short-term use (not maintenance); Medicare Administrative Contractors have discretion to define failure, contraindications, and what constitutes short-term therapy.

"IVIg is covered for the treatment of biopsy-proven Pemphigus Vulgaris, Pemphigus Foliaceus, Bullous Pemphigoid, Mucous Membrane (Cicatricial) Pemphigoid, or Epidermolysis Bullosa Acquisita in patie..."

Sign up to see full coverage criteria, indications, and limitations.